biOasis Receives Compelling Data From Texas Tech University On Its Herceptin(R) BT2111 Program - Yahoo! Finance
biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that research underway at Texas Tech University Health Sciences Center (TTUHSC) has yielded some compelling data on preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of Transcend and Herceptin®) in animal models of breast cancer metastasis to the brain.
Read the full story >>
The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.
The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.
The school, which is the sixth at the university, aims to train future health care leaders in population and public health.
The TTUHSC Jerry H. Hodge School of Pharmacy celebrated the Class of 2022 May 21 with its annual commencement ceremony.